Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial


Bahl A., Oudard S., Tombal B., Ozguroglu M. , Hansen S., Kocak I., ...Daha Fazla

ANNALS OF ONCOLOGY, cilt.24, ss.2402-2408, 2013 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 24 Konu: 9
  • Basım Tarihi: 2013
  • Doi Numarası: 10.1093/annonc/mdt194
  • Dergi Adı: ANNALS OF ONCOLOGY
  • Sayfa Sayıları: ss.2402-2408

Özet

Cabazitaxel significantly improves overall survival (OS) versus mitoxantrone in patients with metastatic castration-resistant prostate cancer after docetaxel failure. We examined patient survival at 2 years and tumour-related pain with cabazitaxel versus mitoxantrone.